Design Therapeutics
DSGN
11.38
-0.31
-2.65%
Design Therapeutics
US · DSGN
#3479 by market cap
Listed 2021
11.38
-0.31
-2.65%
Live - 5344 symbols - heartbeat 195s ago
· 2026-10-08 09:56
Pre-market
11.81
+1.03%
After-hours
11.69
0.00%
- Market cap
- 712.18M
- P/E (TTM)i
- -9.64
- P/Bi
- 3.53
- EPSi
- -1.22
- Div yieldi
- 0.00%
- 52W posi
- 51%
Reader sentiment
Are you bullish or bearish on DSGN?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.09M | 2.50M | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M |
| Research & development | 1.65M | 6.06M | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M |
| Operating profit | -1.91M | -8.33M | -35.83M | -67.59M | -78.19M | -62.38M | -79.47M |
| Pretax profit | -2.05M | -8.28M | -35.53M | -63.31M | -66.86M | -49.59M | -69.79M |
| Tax | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -2.05M | -8.28M | -35.53M | -63.31M | -66.86M | -49.59M | -69.79M |
| Basic EPS | 0 | 0 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.08 | -0.15 | -0.77 | -1.14 | -1.19 | -0.88 | -1.22 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.04M | 5.83M | 4.72M | 4.74M | 5.33M | 5.79M |
| Research & development | 15.38M | 15.74M | 14.59M | 13.43M | 14.38M | 16.39M |
| Operating profit | -20.42M | -21.57M | -19.31M | -18.17M | -19.71M | -22.18M |
| Pretax profit | -17.72M | -19.08M | -17.00M | -16.00M | -17.64M | -20.17M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -17.72M | -19.08M | -17.00M | -16.00M | -17.64M | -20.17M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.31 | -0.34 | -0.30 | -0.27 | -0.29 | -0.32 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 90.00K | 36.23M | 385.44M | 335.12M | 284.58M | 248.04M | 223.78M |
| Cash & ST investments | 77.00K | 36.09M | 384.06M | 330.39M | 281.80M | 245.48M | 219.85M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 90.00K | 36.52M | 390.56M | 341.14M | 289.64M | 252.09M | 226.20M |
| Total current liabilities | 3.73M | 2.33M | 5.28M | 10.78M | 9.62M | 8.46M | 13.06M |
| Short-term debt | 695.00K | -- | 489.00K | 640.00K | 716.00K | 800.00K | 890.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 3,732,000.00 | 47,831,000.00 | 8,427,000.00 | 13,827,000.00 | 11,956,000.00 | 9,996,000.00 | 13,700,000.00 |
| Total equity | -3.64M | -11.32M | 382.13M | 327.31M | 277.69M | 242.10M | 212.50M |
| Retained earnings | -3.64M | -11.92M | -47.46M | -110.76M | -177.63M | -227.21M | -297.01M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 233.64M | 219.79M | 209.03M | 223.78M | 227.05M | 212.01M |
| Cash & ST investments | 229.67M | 216.28M | 205.97M | 219.85M | 222.82M | 207.40M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 237.48M | 222.89M | 211.77M | 226.20M | 230.44M | 215.13M |
| Total current liabilities | 8.24M | 8.75M | 11.17M | 13.06M | 10.19M | 11.24M |
| Short-term debt | 821.00K | 844.00K | 866.00K | 890.00K | 536.00K | 631.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 9,556,000.00 | 9,849,000.00 | 12,050,000.00 | 13,700,000.00 | 12,388,000.00 | 13,271,000.00 |
| Total equity | 227.92M | 213.04M | 199.72M | 212.50M | 218.05M | 201.86M |
| Retained earnings | -244.93M | -264.01M | -281.01M | -297.01M | -314.64M | -334.81M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -139.00K | -8.67M | -29.38M | -51.32M | -58.56M | -43.11M | -54.36M |
| Depreciation & amortization | 0 | 5.00K | 129.00K | 406.00K | 537.00K | 596.00K | 622.00K |
| Free cash flow | -139.00K | -8.75M | -30.92M | -52.24M | -58.82M | -43.45M | -54.55M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 254.27M | -- | -- | 0 | 24.85M |
| Ending cash balance | 77.00K | 2.38M | 298.57M | 26.50M | 21.20M | 22.56M | 16.86M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -16.79M | -14.44M | -11.16M | -11.97M | -16.43M | -15.52M |
| Depreciation & amortization | 159.00K | 152.00K | 155.00K | 156.00K | 157.00K | 151.00K |
| Free cash flow | -16.86M | -14.53M | -11.16M | -12.00M | -16.43M | -15.55M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 19.91M | 0 |
| Ending cash balance | 13.67M | 19.70M | 15.09M | 16.86M | 12.77M | 12.91M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -19.16 | -17.85 | -22.10 | -19.08 | -30.70 |
| ROA %i | -2,274.44 | -45.24 | -16.64 | -17.30 | -21.20 | -18.31 | -29.18 |
| ROIC %i | -- | -- | -18.80 | -17.66 | -21.86 | -23.76 | -34.67 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -21.78 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.02 | 15.55 | 72.96 | 31.10 | 29.58 | 29.31 | 17.14 |
| Quick ratioi | 0.02 | 15.49 | 72.72 | 30.76 | 29.44 | 29.16 | 16.97 |
| Debt / assetsi | 772.22 | 0.00 | 0.93 | 1.08 | 1.05 | 0.93 | 0.68 |
| LT debt / equityi | -- | -- | 0.82 | 0.93 | 0.84 | 0.63 | 0.30 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -22.59 | -26.77 | -29.83 | -30.70 | -31.26 | -34.13 |
| ROA %i | -21.77 | -25.78 | -28.49 | -29.18 | -29.80 | -32.33 |
| ROIC %i | -22.37 | -31.29 | -34.17 | -34.67 | -34.94 | -37.84 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 28.37 | 25.13 | 18.71 | 17.14 | 22.28 | 18.86 |
| Quick ratioi | 28.06 | 24.88 | 18.56 | 16.97 | 22.05 | 18.61 |
| Debt / assetsi | 0.90 | 0.87 | 0.82 | 0.68 | 1.19 | 1.24 |
| LT debt / equityi | 0.58 | 0.52 | 0.44 | 0.30 | 1.01 | 1.01 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Design Therapeutics, Inc.,100.00%
Region
United States100.00%
Quote time 2026-10-08 09:56:28 · For reference only, not investment advice and not tailored to your situation.